2. UroToday Home
  3. Center Of Excellence

Centers of Excellence

Endourology

Curated by clinicians: educational forums with videos, abstracts and conference information
Jaime Landman, MD

Jaime Landman, MD, director of the UCI Health Center for Urological Care, is an internationally recognized urologist and expert in diseases and conditions of the kidneys, including kidney stones and benign and malignant tumors. He is experienced in all forms of minimally invasive kidney surgery, including robot-assisted surgery and percutaneous cryoablation. Dr. Landman, who founded the UCI Health Ablative Oncology Center, has performed more than 2,000 advanced minimally invasive kidney procedures. He is dedicated to improving the techniques and technology associated with minimally invasive surgery.

Videos
Clinical Conversations by Experts
The Impact of Irrigation Fluid Temperature on Thulium Fiber Laser Stone Ablation: An In-Vitro Study "Presentation"
In-vivo Acute Ureteral Dilation using Electromotive Drug Administration (EMDA) in the Porcine Ureter "Presentation"
Ureteral Strictures Following Ureteroscopic Ureteral Wall Injury: A Previously Unidentified Concern “Presentation”
Immersive Virtual Reality for Percutaneous Nephrolithotomy (PCNL): “The More you Know, the Safer and More Effective the Outcome” “Presentation”
Artificial Intelligence Convolutional Neural Network for Efficient and Accurate CT-based Stone Volume Determination “Presentation”
Assessing Alterations in Stone Burden Among Patients with Medullary Sponge Kidney: A Volumetric Approach “Presentation”
Surgical Force-Correlating Science with Practice: A Study of the Fore Exerted by Urologists During Ureteral Access Sheath Placement “Presentation”
Immersive Virtual Reality (iVR) for Percutaneous Nephrolithotomy: The More You Know, the Better the Outcome Presentation - Andrei D. Cumpanas
Head-To-Head Energy Transmission of the Super-Pulse Thulium Fiber Laser Versus Holmium Laser in Multiple Fiber Sizes and Settings Presentation - Allen Rojhani
Clinical Measurement of Maximum Safe Ureteral Distensibility Using a Novel Force Sensor Presentation - Amanda McCormac
Development and Initial Clinical Experience of a Novel Endoscopic Robotic Platform: Monarch PCNL Presentation - Jaime Landman
Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges
Why Not Biopsy? Challenging the Status Quo in Renal Mass Management - Jaime Landman
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
Single-Use Disposable Cystoscopy - Roger Dmochowski, David Chaikin, & Vijay Goli
Antegrade Endoscopic Upper Tract Approaches - Ryan Hsi
Reusable vs. Single-Use Ureterorenoscopes: A Cost-Efficiency Breakdown - Thomas Tailly
Overcoming Misinformation in the Diagnosis and Treatment of Kidney Cancer for Patients and Caregivers - Dena Battle
Surgical Simulator for Laparoscopic Partial Nephrectomy for Renal Cell Carcinoma - Gonzalo Vitagliano
The PDIGREE Trial - Define Rational Sequencing in Combination Treatment of mRCC - Tian Zhang
Effect of 3-Dimensional Virtual Reality Models for Surgical Planning of Robotic-Assisted Partial Nephrectomy on Surgical Outcomes - Ketan Badani
PDIGREE: An adaptive phase III trial of PD-inhibitor Nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI Cabozantinib (CABO) in Metastatic Untreated RCC (Alliance A031704). -Tian Zhang
Kidney Cancer Patient Survey Findings: Impacts from the COVID-19 Pandemic - Dena Battle
Superfluous Hospital Expenditure Associated with Unnecessary Renal Cyst Surveillance - Lee Ponsky & Laura Bukavina
The Use of Active Surveillance in Metastatic Kidney Disease - Jaime Landman and Monty Pal
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic RCC Database Consortium - Shaan Dudani
Surgical and Biomaterial Advances Towards Regeneration of the Lower Urinary Tract - Trinity Bivalacqua
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
The Role of Cytoreductive Nephrectomy in Patients with Metastatic Renal Cell Carcinoma - Neeraj Agarwal, MD
The Dynamic Landscape of mRCC and the PDIGREE Trial - Tian Zhang
Newly Approved Treatment Options for the Management of Metastatic Kidney Cancer- Lauren Harshman and Toni Choueiri
Advances of Systemic Treatments in Renal Cell Carcinoma - Jens Bedke
Targeted Therapies with Immunotherapies In Kidney Cancer - Thomas Powles
Office-based, Ultrasound-Guided Renal Mass Biopsy: Technique and Results - Jaime Landman
Rapidly Evolving Landscape in Metastatic Renal Cell Carcinoma- Rana McKay
Frontline Data from Keynote 426 - Sandy Srinivas
Paradigm Changing Data for Kidney Cancer - Primo Lara
Patient Advocacy and Resources in Kidney Cancer - Dena Battle
Perspectives on the Evolution in Treating Kidney Cancer- Monty Pal and Jaime Landman
Treatment Strategies in Kidney Cancer and the Results of CARMENA - Toni Choueiri
Physician-Scientist Review Articles
State of the Evidence Review Articles
January 29, 2019
The small size and, in benign states, almost inconspicuous appearance of the adrenals belies both their physiologic and pathophysiologic complexity. As a result of this complexity, management of adrenal disorders often requires the involvement of endocrinologists, cardiologists, nephrologists, and anesthesiologists in addition to urologists.
Physician-Scientist Commentaries
Peer-reviewed Abstract Supplemental Commentaries
Written by Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine Urology
Partial nephrectomies are the standard of care with treatment of T1a or T1b tumors due to their better functional outcomes and decrease cardiovascular morbidity.
Written by Zhamshid Okhunov, MD
Department of Urology, University of California, Irvine Urology
Laparoscopic renal surgery (LRS) has long been recognized for its improvements over open renal surgery for patient quality of life.
Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by TEOH Yuen Chun Jeremy, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
The Thursday morning plenary session at the 2024 World Congress of Endourology and Uro-Technology Conference in Seoul was presented by Dr. Jeremy Teoh on the rapidly evolving world of urologic robotics.
Presented by William W. Roberts, MD
The first speaker, Dr. Inderbir Gill, delivered a thought-provoking presentation on the potential of bladder transplantation—a frontier in urology that has yet to be explored in human patients. Dr. Gill began by highlighting the success of transplantation as a treatment for failing major organ systems, such as kidneys, livers, and hearts, as well as non-critical organs like faces, hands, and even penises.
Presented by  Mitchell R. Humphreys, MD
In the moderated poster session for “Stone – Ureteroscopy 2,” Dr. Mitchell R. Humphreys (Mayo Clinic, Phoenix, Arizona) presented his team’s observations on the impact of laser settings for nephrolithiasis specifically using the Thulium fiber laser (TFL).
Presented by Timothy C. Chang, MD
The second plenary session on the first day of the WCET 2024 Conference was initiated with a moderated panel session by Dr. Andrew J. Hung, MD, on the topic of artificial intelligence (AI) in urologic surgery. This included a comprehensive panel of urologists including Dr. Timothy C. Chang, MD of Stanford Urology, Dr. Ahmed Ghazi, MD, FEBU, MHPE of Johns Hopkins, Dr. Russell Terry Jr., MD of UF Health, and Dr. Bhaskar Somani, MRCS, FEBU, FRCS (Urol) of the University of Southampton.
Presented by Mohammad Mohsen Mazloumfard, MD
At the WCET 2024 conference, Shahid Beheshti University of Medical Sciences, presented an insightful study comparing two surgical techniques for the treatment of non-muscle-invasive bladder cancer (NMIBC): Holmium Laser Resection of Bladder Tumor (HoLRBT) and the traditional Transurethral Resection of Bladder Tumor (TURBT).
Presented by Robert Medairos, MD
At the WCET 2024 conference in Seoul, Dr. Robert Medairos from the Department of Urology at Duke University Medical Center presented a study that investigates the potential for thermal injury during the use of the thulium fiber laser (TFL) in stone dusting procedures.
Presented by Bodo Knudsen, MD
 In this edition of the State-of-the-Art lecture series, Dr. Bodo Knudsen provided an extensive overview of the progression and future prospects of laser lithotripsy technologies in endourology. His presentation traced the historical advancements in this field, discussed the current state of the technology, and speculated on future directions. Dr. Knudsen's insights offer a comprehensive guide to both the capabilities and limitations of laser technologies used in the treatment of urinary tract stones.
Presented by Alexander Kutikov, MD, FACS
Alexander Kutikov lead a talk on the surgical complications associated with Robotic Partial Nephrectomy. He starts by highlighting a collaborative review he and I worked on for European Urology that walks through decision making for the management of localized solid renal masses – where a key decision point is the choice to treat the tumor, and at which point, we have to choose between radical nephrectomy, partial nephrectomy, and ablative options.
Presented by Duane D. Baldwin, MD
On the importance of wise radiation administration in urology, Dr. Baldwin, professor of Urology, Director of Urologic Research at Loma Linda University, gave an engaging presentation. In the beginning, in an abdominal-pelvic CT without contrast, patients will receive 10-20 mSV of radiation, i
Presented by Zachary E Tano, MD
The session began with an interesting presentation by Dr. Lauren Poniatowski where she introduced the idea of cognitive task analysis and how it relates to 3D printing of surgical models. She defined three learning domains: psychomotor, emotions/attitudes, and cognitive, which consists of knowledge,
Presented by Robert J. Motzer, MD
On Sunday, September 11, 2022, in Presidential Symposium II at the ESMO Annual Congress, Dr. Motzer presented highly awaited results from the CheckMate 914 trial, examining the role of adjuvant nivolumab and ipilimumab in patients treated with nephrectomy for localized renal cell carcinoma at a high risk of relapse.
Presented by Thomas B. Powles, MBBS, MRCP, MD
The 2022 ESMO annual meeting featured a kidney cancer session, including a discussant presentation by Dr. Tom Powles discussing two key abstracts including “IMmotion010: efficacy and safety from the Phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection” presented by Dr. Axel Bex, and “Phase III RandOmized Study Comparing PErioperative Nivolumab versus Observation in Patients with RCC Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial” presented by Dr. Mohamad Allaf.
Presented by Steven Campbell, MD, PhD
The 2022 Annual Meeting of the American Urological Association was host to an AUA guidelines update session focused on renal masses, presented by Dr. Steven Campbell, MD, PhD.
Presented by Costas Lallas MD, Brian Lane MD, Michigan State University, Lee Ponsky MD, Jaime Landman MD
Friday morning at the 2022 AUA kicked off with a panel discussion consisting of thought leaders in the management of incidentally found 3cm solid renal masses. Dr. Costas Lallas, MD moderated the session which began with four-minute presentations from each panelist.
Presented by David Braun, MD, PhD
During the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on biomarker discovery in renal cell carcinoma (RCC), Dr. David Braun discussed the potential of single-cell RNA sequencing to facilitate biomarker discovery. In doing so, he emphasized how single-cell RNA sequencing can improve our understanding of the underlying biology of RCC, with important implications for both biomarker discovery and therapeutics.
Presented by Samra Turajlic, PhD, MBBS, MRCP
In the tenth session of the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on biomarker discovery in renal cell carcinoma (RCC), Dr. Samra Turajlic presented on the value of T cell receptor (TCR)-related metrics for understanding and predicting the response of immune checkpoint inhibition in clear cell renal cell carcinoma.
Presented by Sam S. Chang, MD, MBA
The SIU 2021 annual meeting included a plenary session with the AUA lecture provided by Dr. Sam Chang discussing the 2021 AUA Guideline for renal masses and localized cancer, specifically evaluation, management, and follow-up.
Presented by Toni K. Choueiri, MD
(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled “Too Many Choices: How to Select the Best Treatment for Your Patient With Kidney Cancer”, Toni Choueiri, MD, presented a plenary talk discussing the subsequent lines of therapy for patients with metastatic renal cell carcinoma (RCC) who have previously received immunotherapy.
Presented by Jaleh Fallah, MD
The 2020 American Society of Clinical Oncologists (ASCO) virtual education program featured a session on the evolution of renal cell carcinoma (RCC) treatment, including a presentation by Dr. Jaleh Fallah from the Cleveland Clinic discussing sequencing and combining targeted and immunotherapy. Over the last couple of years, trials have utilized combination therapy to continue improving outcomes among patients with metastatic RCC. 

 

Presented by Ashkan Malayeri, MD
(UroToday.com) The Society of Urologic Oncology held a virtual meeting on Saturday, July 18, 2020, in place of the usual meeting held at the American Urological Association annual meeting. This virtual meeting was divided into sessions on bladder cancer, kidney cancer, and prostate cancer. In the session on kidney cancer, Ashkan Malayeri, MD, presented an "Update on Emerging and Novel Imaging in Renal Cell Carcinomas (RCCs)," focusing on four areas: radiomics and radiogenomics of RCCs, machine learning and artificial intelligence.
Presented by Axel S. Merseburger, MD, PhD
The virtual EAU 2020 meeting featured a thematic session discussing immunotherapy combinations for intermediate-poor risk metastatic renal cell carcinoma (mRCC). Axel Merseburger, MD, PhD, discussed the utility of combining Immuno-Oncology (IO) treatment with TKIs.
Presented by Toni K. Choueiri, MD
Tyrosine kinase inhibitors and immune checkpoint inhibitors have become standard of care for patients with advanced renal cell carcinoma (RCC). Cabozantinib inhibits tyrosine kinases involved in tumor growth, angiogenesis, and immune regulation, including MET, VEGFR, and TAM kinases (Tyro3, AXL, MER), and may promote an immune-permissive tumor environment, resulting in enhanced response to immune checkpoint inhibitors.
Presented by Rana R. McKay, MD
Checkmate-214 established combination nivolumab/ipilimumab as an effective first-line therapy for patients with metastatic RCC1. Treatment with nivolumab/ipilimumab begins with an induction phase with 4 cycles of ipi/nivo given every 3 weeks, followed by a maintenance phase with nivolumab given every 2 weeks.
Presented by Pavlos Msaouel, MD, PhD
San Francisco, CA (UroToday.com) The incorporation of combination immunotherapy and immunotherapy/anti-angiogenic therapy combinations has changed the first-line treatment landscape
Presented by Ziad Bakouny, MD, MSc
San Francisco, CA (UroToday.com) The role for cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (RCC) was established in the cytokine era. In the current era, with more effective
Presented by Nizar M. Tannir, MD
San Francisco, CA (UroToday.com) Data from CheckMate-214 at 17.5 months of minimum follow-up led to approval of combination nivolumab/ipilimumab for first-line treatment of IMDC
Presented by Adrien Bernstein, MD
Washington, DC (UroToday.com) The second session on renal cell carcinoma at the SUO focused on the management of advanced disease. Dr. Brugarolas was invited to present data
Presented by Suzanne B. Merrill, MD
Washington, DC (UroToday.com) At the kidney cancer session at the 20th Annual Meeting of the Society for Urologic Oncology, Dr. Suzanne Merrill discussed stratified surveillance
Presented by Eoin MacCraith
Athens, Greece (UroToday.com) Dr. Eoin MacCraith continued the PET imaging session with a nice overview of the use of PET-FDG in renal cell carcinoma (RCC)
Presented by Ricardo A. Rendon, MD
Athens, Greece (UroToday.com) Dr. Ricardo Rendon presented on the adjuvant treatment of high-risk renal cell carcinoma (RCC). The cancer-specific survival (CSS)
Presented by Toni K. Choueiri, MD
Barcelona, Spain (UroToday.com) Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is associated with an aggressive phenotype.
Presented by Eric Jonasch, MD
Barcelona, Spain (UroToday.com) Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC)
Presented by Marc-Oliver Grimm, MD
Barcelona, Spain (UroToday.com) In pretreated metastatic renal cell carcinoma (RCC), single agent checkpoint blockade immunotherapy with the PD-1
Presented by Tim Q. Eisen, PhD, MB, BChir
Barcelona, Spain (UroToday.com) Four large, randomized Phase 3 clinical trials (S-TRAC, ASSURE, PROTECT, and ATLAS) evaluated adjuvant VEGF tyrosine kinase inhibitors in patients with resected renal cell carcinoma (RCC).
Presented by Chung-Han Lee, MD, PhD
Barcelona, Spain (UroToday.com) Altered glucose and glutamine metabolism is a hallmark of renal cell carcinoma (RCC). Abnormal glucose metabolism, known as the Warburg effect, deprives the citric acid cycle (TCA cycle) of critical metabolites.
Barcelona, Spain (UroToday.com) Renal tumor biopsy (RTB) for RCC, especially for small renal masses, is recommended by international guidelines if the RTB pathology will change treatment management – either favoring surveillance or ablative therapy. Yet, its usage remains relatively low and uptake is sporadic. Its accuracy is reported to be quite high
Barcelona, Spain (UroToday.com) Renal tumor biopsy (RTB) for renal cell carcinoma (RCC), especially for small renal masses, is recommended by international guidelines if the RTB pathology will change treatment management – either favoring surveillance or ablative therapy. Yet, its usage remains relatively low and uptake is sporadic. Its accuracy is reported to be quite high in more recent series but can be very institutional dependent. 
Presented by Axel Bex, MD, PhD
Barcelona, Spain (UroToday.com) The current standard for advanced localized renal cell carcinoma (RCC) is nephrectomy. Unfortunately, for better or worse, the series of adjuvant therapy
Presented by Marc-Oliver Grimm
Barcelona, Spain (UroToday.com) Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session. He started by highlight that the guidelines for advanced kidney cancer have been revamped recently
Barcelona, Spain (UroToday.com) In this session, Dr. Mir reviewed the role of neoadjuvant therapy in renal cell carcinoma. She reviewed the definition of neoadjuvant therapy, its rationale, how to assess response, the newest data and its future. Neoadjuvant therapy is defined as intervention given prior to primary treatment with the goal of downstaging primary tumors to possibly improve surgical intervention.
Barcelona, Spain (UroToday.com) In this session, Professor Kuczyk heeded caution regarding minimally invasive partial nephrectomy for complex surgical cases. Clinically T1b or T2 disease, endophytic or central tumors have greater risk profiles and should likely be performed at higher volume centers by high volume surgeons. Dr. Kuczyk stated that hospitals are putting pressure on surgeons to attract more business by utilizing newer technology or techniques,
Presented by Daniel Yick Chin Heng, MD, MPH
San Francisco, CA (UroToday.com) Dr. Heng's presentation focused on second- and third-line therapies for metastatic renal cell carcinoma. In order, to decide which 2nd line therapy patients should receive, there are several determinants.
Phoenix, Arizona (UroToday.com) Dr. Tannir gave a discussion on why cytoreductive nephrectomy should not be the standard of care in metastatic renal cell carcinoma (RCC). Dr. Tannir believes that cytoreductive nephrectomy is for intermediate risk patients only. In the cytokine era cytoreductive nephrectomy was shown to prolong overall survival by 6-7 months.1,2
Munich, Germany (UroToday.com) Dr. Laurence Albiges gave a talk on the challenges faced by established frontline therapies in renal cancer. In the ESMO meeting in 2017, the Checkmate 214 trial was presented, which compared sunitinib to Nivolumab + ipilimumab in the treatment of metastatic renal cell carcinoma (mRCC) patients. This trial demonstrated a benefit in favor of the nivolumab + ipilimumab